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Background: For recurrent disease or primary therapy of advanced ovarian cancer, cytoreductive surgery (CRS)
followed by adjuvant chemotherapy is a therapeutic option. The aim of this study was to evaluate the outcome for
patients with epithelial ovarian cancer treated with hyperthermic intraoperative chemotherapy (HIPEC) and
completeness of cytoreduction (CC).
Methods: Data were retrospectively collected from 111 patients with recurrent or primary ovarian cancer operated
with the contribution of visceral surgical oncologists between 1991 and 2006 in a tertiary referral hospital.
Results: Ninety patients received CRS and 21 patients CRS plus HIPEC with cisplatin. Patients with complete
cytoreduction (CC0) were more likely to receive HIPEC. Overall, 19 of 21 patients (90.5 %) with HIPEC and 33 of 90
patients (36.7 %) with CRS had a complete cytoreduction (P< 0.001). Incomplete cytoreduction was associated with
worse survival rates with a hazard ratio (HR) of 4.4 (95%CI: 2.3-8.4) for CC1/2 and 6.0 (95%CI: 2.9-12.3) for CC3
(P< 0.001). In a Cox-regression limited to 52 patients with CC0 a systemic concomitant chemotherapy (HR 0.3, 95%
CI: 0.1-0.96, P = 0.046) but not HIPEC (HR 0.98 with 95 % CI 0.32 to 2.97, P = 0.967) improved survival. Two patients
(9.5 %) developed severe renal failure after HIPEC with absolute cisplatin dosages of 90 and 95 mg.
Conclusions: Completeness of cytoreduction was proved to be crucial for long-term outcome. HIPEC procedures in
ovarian cancer should be performed in clinical trials to compare CRS, HIPEC and systemic chemotherapy against
CRS with systemic chemotherapy. Concerning the safety of HIPEC with cisplatin, the risk of persistent renal failure
must be considered when dosage is based on body surface.
Keywords: Cytoreductive surgery, Peritonectomy, Hyperthermic intraperitoneal chemotherapy, Epithelial ovarian
cancer, Peritoneal carcinomatosisIntroduction
Epithelial ovarian cancer is primarily diagnosed in the
advanced stage III or IV, as defined by FIGO (Inter-
national Federation of Gynaecology and Obstetrics), and
75 % of these patients present with peritoneal carcin-
omatosis as a typical finding [1]. Epithelial ovarian can-
cer is second only to breast cancer as a leading cause of* Correspondence: Thomas.Steffen@kssg.ch
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medium, provided the original work is propergynaecologic cancer-related mortality, with an estimated
14,500 deaths and an estimated 21,550 new cases in
2009 in the United States [2,3]. Disease-free survival
rarely exceeds 18 months after standard therapy [4-6].
The recent 2009 statistics from the American Cancer So-
ciety report an overall survival of 46 %, compared to a
rate of 37 % in 1975 [3].
For recurrent disease or primary therapy of advanced
ovarian cancer (FIGO III and IV), cytoreductive surgery
(CRS) followed by an adjuvant chemotherapy is the stan-
dardized therapeutic option [7]. CRS in combination withss article distributed under the terms of the Creative Commons Attribution
by/2.0), which permits unrestricted use, distribution, and reproduction in any
ly cited.
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also proved feasible, although it is associated with morbid-
ity rates ranging from 0 % to 40 % and mortality rates ran-
ging from 0 % to 10 % [8-11]. In patients with optimal
cytoreduction and HIPEC, a 5-year survival rate ranging
from 12 % to 66 % has been reported. Therefore, HIPEC
after CRS was proposed as the “up-front treatment” for
ovarian cancer with peritoneal carcinomatosis [1], which
was substantially criticized by others [12]. The current
state of knowledge mandates the use of extensive surgery
whenever possible in primary and recurrent ovarian cancer
[13,14]. Ibeanu et al. recommended that surgeons strive
for "no residual disease” as often as possible to improve
survival rates [9]. A residual tumour mass smaller than
2.5 mm is stipulated for the application of HIPEC [11]. To
date, no phase III randomised prospective trial has been
published confirming a benefit of the aggressive treatment
strategy of CRS followed by HIPEC [8]. In addition, identi-
fying which patients will undergo optimal cytoreduction
and consequently qualify for HIPEC remains difficult [9].
Therefore, the abundant heterogeneity in study popula-
tions cannot be prevented because of individual patient se-
lection for HIPEC by operating surgeons and the
presumably variable and individually determined surgical
aggressiveness applied to gain complete cytoreduction.
Nevertheless, results of this treatment modality have been
shown to be beneficial for patients with peritoneal carcin-
omatosis from appendix cancer, applying the same criteria
for cytoreduction and methods for HIPEC [15-17].
The aim of this study was to assess the benefit from
CRS with and without HIPEC and completeness of
cytoreduction (CC) in a consecutive cohort of patients
with advanced (FIGO III or IV) or recurrent ovarian can-
cer with involvement of visceral oncological surgeons for
CRS. The primary endpoint of this study was the survival
of patients. Secondary endpoints were comparison of
CRS alone vs. CRS and HIPEC concerning morbidity
and mortality.Patients and methods
Patient selection
The present study is a retrospective single-institution ob-
servational study. A computer search of the institutional
database was performed. Briefly, we identified 224
patients with ovarian cancer. Of these patients, 113 were
excluded due to the lack of involvement of visceral onco-
logical surgeons. The remaining 111 patients underwent
interdisciplinary operations with the involvement of vis-
ceral oncological surgeons between 1991 and 2006.
These patients had histologically confirmed primary
advanced ovarian cancer (FIGO III or FIGO IV) or re-
current ovarian cancer (independent of initial FIGO
stage).Data collection
Data pertaining to patients’ demographics, operative
details, postoperative mortality, morbidity and histo-
logical results were gathered retrospectively from med-
ical files. Mortality was defined as any death occurring
during the 30 days following surgery. Follow-up data
were obtained from medical records and by contacting
the general practitioners by telephone.Selection criteria for HIPEC
General inclusion criteria for HIPEC were histologically
confirmed primary (FIGO IIIc or IV) or recurrent ovar-
ian carcinoma (independent of initial FIGO stage), age
between 18 and 70 years, ASA stage II or III, informed
consent including explicit consent about the experimen-
tal nature of the HIPEC procedure, adequate renal func-
tion with a renal function of >50 ml/min, no serious
medical condition, no hypersensitivity to cisplatin and no
symptomatic peripheral neuropathy. In patients with pri-
mary advanced ovarian cancers FIGO IIIc that were ini-
tially inoperable due to their poor general condition,
neoadjuvant chemotherapy with three cycles of taxol or
carboplatin was applied. If the patient’s condition
improved (clinical impression), HIPEC was performed.
Patients with primary ovarian carcinoma FIGO IV did
not generally qualify for HIPEC except with fully regres-
sive malignant pleural effusion under chemotherapy with
taxol or carboplatin. Patients with recurrent disease were
included in the absence of a distant metastasis. In
patients with primary or recurrent disease where CC0 or
CC1 was not reached intraoperatively, cytoreduction
without HIPEC was performed. The treatment modality
for each individual patient was determined preopera-
tively by an interdisciplinary tumor board with participa-
tion from the following departments: gynaecology,
visceral surgical oncology, medical oncology, radiology,
radio oncology, and pathology.Dosage of cisplatin in HIPEC
In general, there was a body surface related cisplatin
dose of 50 mg/m2 in HIPEC. The body surface area was
calculated according to Mosteller [18]. In patients with
preoperative renal insufficiency or previous carboplatin
treatment, the dosage was reduced by 30 %.Treatment modality
Peritonectomy was performed as proposed by Sugarba-
ker [11]. CC was assessed according to Sugarbaker: CC0:
no residual disease; CC1: residual disease with nodules
measuring less than 2.5 mm; CC2: residual disease with
nodules measuring between 2.5 mm and 2.5 cm; and
CC3: residual nodules greater than 2.5 cm [11]. All
patients received perioperative antibiotic prophylaxis
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thrombosis with low molecular weight heparin.
In patients with HIPEC, CRS was followed by immedi-
ate direct instillation of heated platinum-based chemo-
therapy to address residual tumour masses [19]. A RanD
PerformerTM LRT device [RanD S.r.l., Medolla (MO),
Italy] was used. During HIPEC, an intra-abdominal
temperature of 42 °C was targeted, and the duration of
the HIPEC was 90 minutes after the target temperature
was reached. After reaching the target temperature, a
surgeon mixed the intraabdominal fluid constantly to
maintain the target temperature. The temperatures were
recorded every 10 min in the HIPEC protocol. In all
patients, renal function was monitored during the
HIPEC procedure. If renal function decreased, patients
were hydrated and furosemide was given.
Statistical analysis
Statistical analysis was performed using SPSS 11.5 soft-
ware. Continuous data are expressed as mean ± standard
deviation (range). A two-sided P value< 0.05 was consid-
ered to indicate statistical significance. Confidence inter-
vals (95 % CI) of binominal proportions were estimated
according to a Wilson method [20]. Survival time was
calculated from the time of operation. For univariate sur-
vival analysis, log-rank tests were performed. For multi-
variate survival analysis, a full Cox-regression model
with additional variable selection was applied. The R
statistical software using the bootStepAIC package was
used for bootstrapping the backward variable selection
process from the full Cox-regression model [21].
Authorization
The analysis of patient data was approved by the Swiss
Federal Expert Commission for Physician Confidentiality.




From 1991 to 2006, a total of 111 patients with either
advanced (FIGO ≥ III) or recurrent ovarian cancer were
treated with an interdisciplinary approach at a tertiary
referral hospital with the contribution of visceral surgical
oncologists and gynaecologists. A total of 21 (19 %) of
the 111 patients had CRS and HIPEC and 90 (81 %) had
CRS only. Table 1 lists the baseline characteristics of the
two groups. No statistically significant differences in
these characteristics were identified.
Operative and peri-operative outcome
The mean operation time was significantly longer in the
HIPEC group at 8.2± 1.6 h (range: 4.3–11 h) compared to
4.5± 1.7 h in the group without HIPEC (range: 1.5–9.0 h)(P< 0.001). While all patients in the HIPEC group were
postoperatively admitted to the intensive care unit, signifi-
cantly fewer patients of the non-HIPEC group were admit-
ted to the intensive care unit [21/21 (100 %) vs. 65/90
(72.2 %); P=0.007]. The mean number of resected periton-
eum areas was significantly higher in the HIPEC group at
4.5± 1.8 (range: 1–7) compared to 2.0± 1.0 (range: 0–7) in
the group without HIPEC (P< 0.001). Additionally, the
mean number of organs involved in the resection was sig-
nificantly higher in the HIPEC group at 5.5 ± 1.7 (range:
2–8) compared to 1.7± 4.0 (range: 1–9) in the group with-
out HIPEC (P< 0.001). For the more extensive resections,
significantly better CC scores were observed in patients in
the HIPEC group: 19 patients (90.5 %) had a CC0 score, 2
patients (9.5 %) had a CC1 or CC2 score, and none of the
patients who had HIPEC had a CC3 score. In the group
without HIPEC, 33 patients (36.7 %) had a CC0 score, 37
patients (41.1 %) a CC1 or CC2 score, and 20 patients
(22.7 %) had a CC3 score (P< 0.001). The mean body sur-
face related dosage of cisplatin in HIPEC was
40.2 ± 7.8 mg/m2 with a range of 29.6-50.9 mg/m2. In 11
out of 21 patients receiving HIPEC, a body surface related
cisplatin dose of about 50 mg/m2 was generally adminis-
tered. In the other 10 patients with HIPEC, the cisplatin
dose was reduced by 30 % due to preoperative renal insuf-
ficiency (3 patients), previous carboplatin treatment (4
patients) or both (3 patients). The mean absolute dosage
of cisplatin was 69.8± 14.6 mg with a range of 50–95 mg.
Morbidity and mortality
In the HIPEC group, 6/21 patients (28.6 %, 95 % CI:
13.6 %–50.2 %) developed surgical complications com-
pared to 24/90 patients (26.7 %, 95 % CI: 18.6 %–36.7 %)
in the group without HIPEC (P= 0.784). In the HIPEC
group, 7/21 patients (33.3 %, 95 % CI: 17.0 %–54.8 %)
developed general complications compared to 33/90
(36.7 %, 95 % CI: 27.4 %–47.0 %) in the group without
HIPEC (P= 0.985). Ten patients in the group without
HIPEC died within 30 days after their operation (11.1 %,
95 % CI: 6.0 %–19.4 %), while no patients in the HIPEC
group died within the first 30 days after their operation
(95 % CI: 0.0 %–18.2 %) (P= 0.131). The causes of death
were cardial or pulmonary insufficiency in four patients,
sepsis in three patients, multiorgan failure in two
patients, and a pulmonary embolism in one patient. In
the HIPEC group, 3/21 patients (14.3 %, 95 % CI: 4.1 %–
35.5 %) required a second operation compared to 13/90
patients (14.4 %, 95 % CI: 8.5 %–23.3 %) in the group
without HIPEC (P= 0.985). Major surgical complications
in the HIPEC group were postoperative bleeding (N= 1),
wound infection (N= 4), and anastomotic leakage
(N= 1). In addition to pulmonary complications (N= 4),
two patients in the HIPEC group (9.5 %) developed se-
vere persistent renal failure. Further analysis revealed a
Table 1 Baseline characteristics
Total HIPEC; N= 21 Operation only; N= 90 P
Disease Primary disease 53 (47.7%) 10 (47.6%) 43 (47.8%) 0.990 B)
Recurrent disease** 58 (52.3%) 11 (52.4%) 47 (52.2%)
Recurrent disease:
time since diagnosis
Months 40.9 ± 44.2 51.7 ± 70 38.3 ± 36.3 0.960 A)
Initial/actual FIGO stageC) FIGO IIa 1 (0.9%) 1 (4.8%) 0 (0%) 0.638 A)
FIGO IIc 4 (3.6%) 2 (9.5%) 2 (2.2%)
FIGO IIIa 1 (0.9%) 0 (0.0%) 1 (1.1%)
FIGO IIIb 11 (9.9%) 2 (9.5%) 9 (10.0%)
FIGO IIIc 72 (64.9%) 11 (52.4%) 61 (67.8%)
FIGO IV 22 (19.8%) 5 (23.8%) 17 (18.9%)
Age at operation Years 63.8 ± 12.1 58.9 ± 11.4 65.0 ± 12.0 0.064 A)
Hospitalization time Days 28.5 ± 14.3 32.9 ± 18.2 27.5 ± 13.1 0.292 A)
Body mass index kg/m² 25.3 ± 5.9 25.7 ± 4.7 25.1 ± 6.2 0.441 A)
Follow-up, survivors Months 35.6 ± 35.3 29.4 ± 15.4 38.3 ± 40.9 0.824 A)
ASA stage D) I 1 (0.9%) 0 (0.0%) 1 (1.1%) 0.103 A)
II 71 (64.0%) 17 (81.0%) 54 (60.0%)
III 38 (34.2%) 4 (19.0%) 34 (37.8%)
IV 1 (0.9%) 0 (0.0%) 1 (1.1%)
Initial grading G1 7 (6.3%) 3 (14.3%) 4 (4.4%) 0.414 A)
G2 30 (27.0%) 5 (23.8%) 25 (27.8%)
G3 65 (58.6%) 13 (61.9%) 52 (57.8%)
G4 3 (2.7%) 0 (0.0%) 3 (3.3%)
GX 1 (0.9%) 0 (0.0%) 1 (1.1%)
Initial tumor growth
pattern
Serous 87 (78.4%) 16 (76.2%) 71 (78.9%) 0.484 B)
Mucinous 2 (1.8%) 1 (4.8%) 1 (1.1%)
Endometrioid 10 (9.0%) 3 (14.3%) 7 (7.8%)
Clear cell 2 (1.8%) 0 (0.0%) 2 (2.2%)
Other 4 (3.6%) 0 (0.0%) 4 (4.4%)
Concomitant radiation 4 (3.6%) 0 (0.0%) 4 (4.4%) 0.325 B)
Concomitant
chemotherapy
Total 75 (67.6%) 14 (66.7%) 61 (67.8%) 0.922 B)
Carboplatin 56 (50.5%) 13 (61.9%) 43 (47.8%) 0.244 B)
Taxol 14 (12.6%) 4 (19.0%) 10 (11.1%) 0.324 B)
Endoxan 4 (3.6%) 0 (0.0%) 4 (4.4%) 0.325 B)
Other 20 (18.0%) 2 (9.5%) 18 (20.0%) 0.216 B)
Mean± standard deviation
N (%)A) Mann–Whitney U-Test
B) Chi-square test
C) initial FIGO stage for recurrences and actual FIGO stage for primary disease
FIGO: International Federation of Gynecology and Obstetrics
D) ASA: American Society of Anesthesiologists
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platin but not with the body surface related dosage.
Mean absolute dosage of cisplatin in the two patients
with persistent renal failure was 92.5 ± 3.5 mg (range:
90–95 mg) compared to 67.4 ± 13.2 mg (range: 50–
90 mg) (P= 0.026). The body surface related dosage of
cisplatin in the two patients with persistent renal failurewas 46.7 ± 2.1 mg (range: 45.2–48.2 mg) compared to
39.5 ± 7.8 mg (range: 29.6–50.9 mg) (P= 0.338).
Survival analysis
For the 52 patients with a CC0 score, the 2- and 5-year
survival rates were 71.0 % and 63.0 %, respectively. For
the 39 patients with a CC1 or CC2 score, the 2- and 5-
Figure 2 Patient benefit from HIPEC. In the HIPEC group, 2- and
5-year survival rates were each 72.5%, compared to patients with
CRS only (CC3 score excluded) with 2- and 5-year survival rates at
52.0% and 38.3%, respectively (N= 70; P= 0.043).
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For the remaining 20 patients with a CC3 score, the 2-year
survival rate was 17.5 % whereas no patient survived
5 years (P< 0.001) (Figure 1). Incomplete cytoreduction
was associated with significantly worse survival rates in
Cox regression analysis with a hazard ratio (HR) of 4.4
(95%CI: 2.3-8.4) for CC1/2 and 6.0 (95%CI: 2.9-12.3) for
CC3. No relevant difference in the 5-year survival rate was
found concerning the patients undergoing a primary oper-
ation (N=53) versus those with recurrent disease (N=58)
(P=0.944, 5-year survival of 36.0 % versus 32.7 %). In the
HIPEC group, the 2- and 5-year survival rates were each
72.5 %. This outcome was compared to that for patients
with CRS only after excluding patients with a CC3 score.
The 2- and 5-year survival rates in this subgroup were
52.0 % and 38.3 %, respectively (N=70; P=0.043).
(Figure 2)
To evaluate the influence of the cisplatin dosage on
survival, patients with HIPEC were post hoc divided into
high- and low-dose groups dichotomised at the median
absolute dosage of 70 mg. There was no significant dif-
ference in 5-year survival rates between these two groups
(70.0 % versus 76.2 %; P= 0.691).
Finally, a multivariate Cox-regression analysis was per-
formed. This analysis was limited to the 52 patients with
CC0 score (19 with HIPEC and 33 without HIPEC) to
avoid a bias from the collinearity of HIPEC and CC
score. In this analysis, systemic chemotherapy was the
only significant predictor for survival (P = 0.038). HIPEC
(P= 0.830), primary operation versus operation after re-
lapse (P= 0.349), initial FIGO stage (P= 0.964), and age
(P= 0.541) did not significantly influence survival. In aFigure 1 Influence of completeness of cytoreduction on
survival. Completeness of cytoreduction correlates significantly
with survival (N = 111; P< 0.001).limited Cox-regression model, HIPEC (HR 0.98 with
95 % CI 0.32 to 2.97, P = 0.967) did not add a predictive
value for survival to systemic chemotherapy (HR: 0.33
with 95 % CI 0.12 to 0.96, P = 0.046). A lack of significant
predictive value of HIPEC for survival was confirmed in
a stepwise backward and forward variable selection pro-
cedure. In contrast, a bootstrapping procedure of the
backward variable selection indicated a beneficial effect
of HIPEC for survival. HIPEC was selected in 89.19 % of
9999 permutated samples as a relevant predictor with a
beneficial effect in 99.97 % (Table 2).Table 2 Multivariate Cox-regression model and
bootstrapping
Cox regression model A) Bootstrap B)




Age [years] 0.541 1.016 0.966 1.069 94.75 100.00
Systemic
chemotherapy
0.038 0.279 0.084 0.932 90.32 0.00
Recurrent disease 0.349 0.558 0.163 1.908 30.83 15.21
FIGO IV vs. III/II 0.964 0.964 0.199 4.676 21.60 63.29
HIPEC 0.830 0.881 0.275 2.820 89.19 0.03
Analysis limited to 52 patients with CC0 score
A) Full Cox-regression model. Additionally, backward and forward variable
selections identified systemic chemotherapy as the only independent
significant predictor for survival
B) Bootstrapping procedure for backward variable selection process with 9999
samples. Column selection expresses the fraction indicating how often the
variable was selected in the backward variable selection process and column
HR> 1 expresses the fraction of a hazard ratio above 1.0
C) Likelihood ratio test
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This study confirmed CC, systemic concomitant chemo-
therapy, and age as significant independent factors influ-
encing the survival rate. According to previously
published literature, incomplete cytoreduction (CC
scores>CC0) was associated with the worst outcome
reflected by a HR of 4.7 in patients with CC1 or CC2
and a HR of 5.3 in patients with CC3, respectively
[13,22,23]. This finding suggests that all efforts must tar-
get maximal cytoreduction. As already shown in a meta-
analysis [14], the benefit of maximal cytoreduction in the
present study was not limited to primary disease; the
same effect was found in patients with recurrent disease.
While HIPEC appeared to significantly improve survival
rates in univariate analysis, no independent benefit of
HIPEC on survival was demonstrated on multivariate
analysis when limiting it to the 52 patients with CC0
score to exclude a bias from collinearity between CC
score and HIPEC. This lack of evidence for a benefit of
HIPEC on survival is in contrast to previous findings
from various studies reporting also “non-randomised ex-
perience” [12]. However, repeating the statistical variable
selection process in 9999 permutated samples of the ori-
ginal data, HIPEC was selected in 89 % as a predictor for
survival and was associated with a beneficial effect in
more than 99 %. This finding suggests that the lacking
influence of HIPEC in conventional analysis might be
caused by low power and collinearity [21].
The presented data inherits a strong selection bias in
favour to HIPEC. Complete cytoreduction was signifi-
cantly more often achieved in patients receiving HIPEC.
As a tendency, patients with HIPEC were younger and
presented with less advanced ASA stages. Mortality was
limited to patients not receiving HIPEC. This selection
bias may well explain the significant benefit of HIPEC on
survival in univariate analysis. On the other hand, the
lack of significance in multivariate analysis might theor-
etically be attributed to a small sample size. In addition,
it is important to note that this study was limited to a
single centre cohort that underwent operations between
1991 and 2006 at a “low volume” hospital for HIPEC in
ovarian cancer. As the present study has a retrospective
observational study design, manifold other forms of bias
cannot be ruled out, although partly anticipated in multi-
variate analyses. Nevertheless, there is some evidence
that results from observational studies are often similar
to those of clinical trials [24]. Also, in the light of the re-
cently developed Comparative Effectiveness Research
(CER), observational studies are valuable as they might
help clinicians in their decision process.
Morbidity was comparable in patients with and with-
out HIPEC. Operation time was significantly longer in
the HIPEC group, even taking into account about 2 h for
performing a HIPEC procedure. Moreover, patients withHIPEC were more likely to be admitted to the intensive
care unit. Therefore, the potential benefit of HIPEC has
to be weighted critically against the additional effort.
The safety analysis revealed two patients with renal
failure after HIPEC with a high absolute cisplatin dosage
of 90 mg and 95 mg, respectively. It is important to con-
sider the relevant risk of renal failure after HIPEC and to
avoid overdosage, especially as there was no dose-
dependent survival benefit in this study [25]. Although
there is a correlation between body surface and blood
volume, the pharmacodynamics of drugs dosed by the
body surface is still highly variable and thus dosing on
the body surface is increasingly considered controversial
for systemic administration [26]. For HIPEC, dosing by
the body surface is even more questionable, given that
the aim is the highest possible drug concentration in the
peritoneum without undue local and systemic toxicity
[27]. Since the amount of cytotoxic drug is fixed by dos-
ing on the body surface, the effective concentration in
the perfusate can vary considerably between patients
[28,29]. Pharmacokinetic analyses have shown that redu-
cing the concentration of the cytotoxic drug in the per-
fusate reduces the efficacy even if the amount of the
drug remains the same [30]. Concerning the safety of cis-
platin dosing, our data suggest a harmful effect, even at
the body surface related dose of 50 mg/m² cisplatin. Due
to the occurrence of renal failure after administra-
tion of the usual cisplatin dose a prospective study,
“HIPEC of Recurrent Ovarian Cancer - A Feasibility
Study” (NCT00968799), was initiated and is presently
recruiting.Conclusion
In conclusion, this study has provided some evidence in-
dicating that the completeness of cytoreduction is crucial
for a long-term positive outcome. The removal of all evi-
dent macroscopic disease should be the goal of primary
and secondary cytoreductive surgery in ovarian cancer.
The present study failed to identify an independent
benefit of HIPEC. Until evidence-based prove of signifi-
cant therapeutic benefit, HIPEC procedures in ovarian
cancer should be embedded in clinical trials favourably
comparing CRS, HIPEC and systemic chemotherapy
against CRS with systemic chemotherapy only. Finally,
for HIPEC, the dosing regime should be carefully
evaluated.Competing interests
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